Indicated as a complete regimen for the treatment of HIV-1 infection in patients weighing at least 35 kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey

Indicated for the treatment of HIV-1 infection, in combination with other antiretroviral agents

Indicated for the treatment of HIV-1 infection

In combination with other antiretrovirals, this drugs is indicated for treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection

Indicated for the treatment of HIV-1 infection

Indicated to reduce the risk of HIV-1 infection

This is the first time a generic has been approved for Kaletra. For the treatment of HIV-1 infection

This is the first time a generic has been approved for Intelence. For the treatment of HIV-1 infection in treatment-experienced patients

A complete regimen for the treatment of HIV-1 infection to replace current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no history of treatment failure. This is the first FDA-approved injectable, complete regimen for HIV, administered once a month

Indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection